Current status and recent progress of nanomaterials in transcatheter arterial chemoembolization therapy for hepatocellular carcinoma  

作　　者：Jia Sun Hai-Liang Li Wen-Jun Zhou Zeng-Xin Ma Xiao-Pei Huang Cheng Li 

机构地区：[1]Department of Hepatobiliary Pancreatic Hernia Surgery,The Affiliated Guangdong Second Provincial General Hospital of Jinan University,Guangzhou 510317,Guangdong Province,China

出　　处：《World Journal of Clinical Oncology》2025年第4期66-78,共13页世界临床肿瘤学杂志(英文)

摘　　要：Hepatocellular carcinoma(HCC)remains one of the most common cancers worldwide.Transcatheter arterial chemoembolization has become a common treatment modality for some patients with unresectable advanced HCC.Since the introduction of nanomaterials in 1974,their use in various fields has evolved rapidly.In medical applications,nanomaterials can serve as carriers for the delivery of chemotherapeutic drugs to tumour tissues.Additionally,nanomaterials have potential for in vivo tumour imaging.This article covers the properties and uses of several kinds of nanomaterials,focusing on their use in transcatheter arterial chemoembolization for HCC treatment.This paper also discusses the limitations currently associated with the use of nanomaterials.

关 键 词：Transcatheter arterial chemoembolization Hepatocellular carcinoma NANOMATERIALS Drug delivery system CHEMOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]